http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#Head http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#assertion http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#provenance http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#pubinfo http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#assertion http://purl.obolibrary.org/obo/DOID_8504 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8504 http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01112 http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association http://www.w3.org/2000/01/rdf-schema#label note cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram per milligram basis see clinical pharmacology cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen pharyngitis tonsillitis note acute bacterial otitis media impetigo to reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs cefuroxime axetil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01112 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#provenance http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#pubinfo http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig http://purl.org/nanopub/x/hasSignature Em/cR/09W5oCB5MZE1Ra5WHajEfi2Mco0zissgbQv5d+ArrumGMQhYfPz8FEYwAlqFJKBkJPUT7FDtWskE+0zE9NUK1pWonNo+E/URksmltqiX7YwV89mVrgrv1zCAR2GVFes2/lRNJC9lUACtVkCdnWJW93TMavOLOaJNeAbZk= http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE http://purl.org/dc/terms/created 2021-06-13T16:35:11.551+02:00 http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA_suF3uUEGyB0Bz1MKkqA2M1oLA-BClO_1mmr4KbxGsE https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs